Background Myocardial injury has been found using magnetic resonance imaging in recovered coronavirus disease 2019 (COVID‐19) patients unselected or with ongoing cardiac symptoms. Purpose To evaluate for the presence of myocardial involvement in recovered COVID‐19 patients without cardiovascular symptoms and abnormal serologic markers during hospitalization. Study Type Prospective. Population Twenty‐one recovered COVID‐19 patients and 20 healthy controls (HC). Field Strength/Sequence 3.0 T, cine, T2‐weighted imaging, T1 mapping, and T2 mapping. Assessment Cardiac ventricular function includes end‐diastolic volume, end‐systolic volume, stroke volume, cardiac output, left ventricle (LV) mass, and ejection fraction (EF) of LV and right ventricle (RV), and segmental myocardial T1 and T2 values were measured. Statistical Tests Student's t ‐test, univariate general linear model test, and chi‐square test were used for analyses between two groups. Ordinary one‐way analyses of variance or Kruskal–Wallis H test were used for analyses between three groups, followed by post‐hoc analyses. Results Fifteen (71.43%) COVID‐19 patients had abnormal magnetic resonance findings, including raised myocardial native T1 (5, 23.81%) and T2 values (10, 47.62%), decreased LVEF (1, 4.76%), and RVEF (2, 9.52%). The segmental myocardial T2 value of COVID‐19 patients (49.20 [46.1, 54.6] msec) was significantly higher than HC (48.3 [45.2, 51.7] msec) ( P < 0.001), while the myocardial native T1 value showed no significant difference between COVID‐19 patients and HC. The myocardial T2 value of serious COVID‐19 patients (52.5 [48.1, 57.1] msec) was significantly higher than unserious COVID‐19 patients (48.8 [45.9, 53.8] msec) and HC (48.3 [45.2, 51.7]) ( P < 0.001). COVID‐19 patients with abnormally elevated D‐dimer, C‐reactive protein, or lymphopenia showed higher myocardial T2 values than without (all P < 0.05). Data Conclusion Cardiac involvement was observed in recovered COVID‐19 patients with no preexisting cardiovascular disease, no cardiovascular symptoms, and elevated serologic markers of myocardial injury during the whole course of COVID‐19. Level of Evidence 1 Technical Efficacy Stage 5

Some new radiotracers might add useful information and improve diagnostic confidence of 18 F-FDG imaging in tumors. A multicenter clinical trial was designed to investigate the diagnostic performance of dual-tracer ( 18 F-FDG and 39-deoxy-39-18 F-fluorothymidine [ 18 F-FLT]) PET/CT in pulmonary nodules. Methods: Fifty-five patients underwent dual-tracer imaging in 6 imaging centers using the same models of equipment and standardized protocols. The images were interpreted by a collective group of readers who were unaware of the clinical data. The diagnostic performance using either tracer alone or dual-tracers together, with or without CT, was compared. The histological diagnosis or clinical findings in a 12-mo follow-up period served as the standard of truth. Results: In 16 patients with malignant tumor, 16 with tuberculosis, and 23 with other benign lesions, the sensitivity and specificity of 18 F-FDG and 18 F-FLT were 87.5% and 58.97% and 68.75% and 76.92%, respectively. The combination of dual-tracer PET/CT improved the sensitivity and specificity up to 100% and 89.74%. The 3 subgroups of patients could be best separated when the 18 F-FLT/ 18 F-FDG standardized uptake value ratio of 0.4-0.90 was used as the threshold. Conclusion: By reflecting different biologic features, the dualtracer PET/CT using 18 F-FDG and 18 F-FLT favorably affected the diagnosis of lung nodules.

Background and objectivesCoronavirus disease 2019 is spreading rapidly across the world. This study aimed to assess the characteristics of kidney injury and its association with disease progression and death of patients with coronavirus disease 2019.Design, setting, participants, & measurementsThis is a retrospective study. Two representative cohorts were included. Cohort 1 involved severe and critical patients with coronavirus disease 2019 from Wuhan, China. Cohort 2 was all patients with coronavirus disease 2019 in Shenzhen city (Guangdong province, China). Any kidney injury was defined as the presence of any of the following: hematuria, proteinuria, in-hospital AKI, or prehospital AKI. AKI was defined according to the Kidney Disease Improving Global Outcomes (KDIGO) creatinine criteria. The primary outcome was death at the end of follow-up. The secondary outcome was progression to critical illness during the study period.ResultsA total of 555 patients were enrolled; 42% of the cases (229 of 549) were detected with any kidney injury, 33% of the cases (174 of 520) were detected with proteinuria, 22% of the cases (112 of 520) were detected with hematuria, and 6% of the cases (29 of 520) were detected with AKI. Of the 29 patients with AKI, 21 cases were recognized as in-hospital AKI, and eight were recognized as prehospital AKI. Altogether, 27 (5%) patients died at the end of follow-up. The death rate was 11% (20 of 174) in patients with proteinuria, 16% (18 of 112) in patients with hematuria, and 41% (12 of 29) in the AKI settings. Multivariable Cox regression analysis showed that proteinuria (hazard ratio, 4.42; 95% confidence interval, 1.22 to 15.94), hematuria (hazard ratio, 4.71; 95% confidence interval, 1.61 to 13.81), and in-hospital AKI (hazard ratio, 6.84; 95% confidence interval, 2.42 to 19.31) were associated with death. Among the 520 patients with noncritical illness at admission, proteinuria (hazard ratio, 2.61; 95% confidence interval, 1.22 to 5.56) and hematuria (hazard ratio, 2.50; 95% confidence interval, 1.23 to 5.08) were found to be associated with progression to critical illness during the study period.ConclusionsKidney injury is common in coronavirus disease 2019, and it is associated with poor clinical outcomes.PodcastThis article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2020_09_18_CJN04780420.mp3

Radiotherapy for patients with NPC caused radiation-induced changes of the thyroid gland. The shrinkage of the gland was greatest in the first 6 months after radiotherapy, whereas the serum fT4 and TSH levels changed at 12 months. Radiation-induced changes were dependent on the mean dose to the gland. Therefore, measures to reduce the thyroid dose in radiotherapy should be considered.